<DOC>
	<DOCNO>NCT01191190</DOCNO>
	<brief_summary>Patients relapsed/refractory CLL require therapy per iwCLL guideline eligible . Subjects receive treatment ofatumumab HDMP three consecutive 4 week cycle . The primary endpoint determine complete response ( CR ) therapy secondary endpoint assess safety tolerability regimen , impact treatment progression free , treatment free , overall survival , pharmacokinetics ofatumumab . Patients receive allopurinol tumor-lysis prophylaxis antimicrobial prophylaxis .</brief_summary>
	<brief_title>Ofatumumab High-dose Methylprednisolone Patients With Chronic Lymphocytic Leukemia ( CLL )</brief_title>
	<detailed_description>Patients relapsed/refractory CLL require therapy per iwCLL guideline eligible . Subjects receive treatment ofatumumab HDMP three consecutive 4 week cycle . The primary endpoint determine complete response ( CR ) therapy secondary endpoint assess safety tolerability regimen , impact treatment progression free , treatment free , overall survival , pharmacokinetics ofatumumab . Cycles 1-3 administer without schedule interruption every 28 day total 12 week therapy . Patients receive allopurinol tumor-lysis prophylaxis antimicrobial prophylaxis . Blood glucose level monitor immediately HDMP infusion finger stick glucometry . Two month follow completion treatment response assessment occur per iwCLL guideline . The treatment administer outpatient , cycle four week duration .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Previously treat patient diagnosis CLL 2 . Previous treatment monoclonal antibody chemotherapy regardless response define iwCLL Working Group Guidelines evidence : progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia massive ( i.e . least 6cm left costal margin ) progressive symptomatic splenomegaly massive node ( i.e . least 10cm long diameter ) progressive symptomatic lymphadenopathy . progressive lymphocytosis increase 50 % 2month period lymphocyte double time ( LDT ) less 6 month . autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid standard therapy ( See Section 10.2 ) 3 . Constitutional symptom , define one follow diseaserelated symptom sign : unintentional weight loss 10 % within previous 6 month significant fatigue ( i.e . ECOG PS 2 worse , inability work perform usual activity ) , fevers high 100.5ºF 38.0ºC 2 week without evidence infection , night sweat 1 month without evidence infection 4 . Subjects must 18 year age old , male female . 5 . ECOG performance status 02 . 6 . Subjects must able give informed consent . 7 . Females child bear potential ( FCBP ) † must negative serum urine pregnancy test within 10 14 day prior within 24 hour start treatment agree use medically accept contraceptive method duration study . 1 . Hepatitis BsAg positive , Hepatitis BcAb positive , Hepatitis C positive patient . 2 . Known HIV positive patient . 3 . Diabetics . 4 . Patients uncontrolled Autoimmune Hemolytic Anemia ( AIHA ) autoimmune thrombocytopenia ( ITP ) . 5 . Screening laboratory value within range : platelet &lt; 50 x 109/L , neutrophil &lt; 1.0 x 109/L , creatinine &gt; 2.0 time upper normal limit , total bilirubin &gt; 1.5 time upper normal limit ( unless know history Gilbert 's disease ) , ALT &gt; 2.5 time upper normal limit ( unless due disease involvement liver ) , alkaline phosphatase &gt; 2.5 time upper normal limit ( unless due disease involvement liver bone marrow ) 6 . Inability provide inform consent . 7 . Concurrent malignancy ( exclude basal squamous cell skin cancer ) . 8 . Active fungal , bacterial , and/or viral infection . 9 . History peptic ulcer disease result GI bleeding within last 6 month . 10 . Untreated metabolic disorder hypothyroidism Cushing 's disease . 11 . History steroidinduced psychosis . 12 . Estimated life expectancy le 3 month investigator 's best clinical judgment . 13 . Serious medical condition would render subject medically unstable . 14 . Women pregnant breastfeeding . 15 . History Pancreatitis . 16 . History Diverticulitis . 17 . Patients know hypersensitivity ofatumumab know history anaphylaxis Rituximab alemtuzumab . 18 . Concurrent use anticancer agent treatment . 19 . Subjects current active hepatic biliary disease ( exception patient Gilbert 's syndrome , asymptomatic gallstone , liver metastasis stable chronic liver disease per investigator assessment ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Leukemia</keyword>
	<keyword>Chronic leukemia</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Relapsed</keyword>
	<keyword>Refractory</keyword>
</DOC>